Human Reproduction, Vol. 19, No. 5, 1237,
May 2004
© 2004 European Society of Human Reproduction and Embryology
Reply: LH/HCG as a monthly injectable contraceptive
Endocrinology Research and Development, Ipsen International, 24, rue Erlanger, 75781 Paris Cedex 16, France
1 To whom correspondence should be addressed. e-mail: ernest.loumaye{at}ipsen.com
Dear Sir,
We thank Drs H.N.Sallam and A.N.Sallam for reminding us of their work in which an injection of HCG during the late follicular phase of a spontaneous cycle was shown to impair follicular development (Sallam and Sallam, 2004
). Their observation nicely concurs with the general concept of the deleterious impact of excessive LH/HCG exposure during follicle growth.
Our work (Loumaye et al., 2003) as well as that of others has also shown that antral follicles are quite tolerant to LH/HCG and that secondary follicles may be more sensitive to LH/HCG than dominant follicles. The clinical challenge remains to define the optimal dose and timing of LH or HCG, to selectively ablate secondary follicles when mono-ovulation is the therapeutic objective.
References
Loumaye E, Engrand P, Shoham Z, Hillier SG and Baird DT (2003) Clinical evidence for an LH ‘ceiling’ effect induced by administration of recombinant human LH during the late follicular phase of stimulated cycles in World Health Organization type I and type II anovulation. Hum Reprod 18,314–322.
Sallam HN and Sallam AN (2004) LH/HCG as a monthly injectable contraceptive? Hum Reprod 19,
December 9, 2003 January 8, 2004
CiteULike 
Connotea 
Del.icio.us What's this?
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||